Now showing items 1160-1179 of 3383

    • Fever of Unknown Origin: the Value of FDG-PET/CT. 

      Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)
      Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ...
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

      Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)
      BACKGROUND:Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; White, IJ; Benjamin, AC; Dertschnig, S; Horsnell, HL; Kriston-Vizi, J; Burden, JJ; Huang, PH; Tape, CJ; Acton, SE (2019-11)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...
    • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). 

      Darabi, H; Beesley, J; Droit, A; Kar, S; Nord, S; Moradi Marjaneh, M; Soucy, P; Michailidou, K; Ghoussaini, M; Fues Wahl, H; Bolla, MK; Wang, Q; Dennis, J; Alonso, MR; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, J; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Broeks, A; Brüning, T; Burwinkel, B; Chang-Claude, J; Choi, J-Y; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Devilee, P; Dörk, T; Easton, DF; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Goldberg, MS; González-Neira, A; Guénel, P; Haiman, CA; Hallberg, E; Hamann, U; Hartman, M; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Johnson, N; Kang, D; Khan, S; Kosma, V-M; Kriege, M; Kristensen, V; Lambrechts, D; Le Marchand, L; Lee, SC; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Mayes, R; McKay, J; Meindl, A; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olswold, C; Orr, N; Peterlongo, P; Pita, G; Pylkäs, K; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Seynaeve, C; Shah, M; Shen, C-Y; Shu, X-O; Southey, MC; Stram, DO; Surowy, H; Swerdlow, A; Teo, SH; Tessier, DC; Tomlinson, I; Torres, D; Truong, T; Vachon, CM; Vincent, D; Winqvist, R; Wu, AH; Wu, P-E; Yip, CH; Zheng, W; Pharoah, PDP; Hall, P; Edwards, SL; Simard, J; French, JD; Chenevix-Trench, G; Dunning, AM (2016-09-07)
      Genome-wide association studies have found SNPs at 17q22 to be associated with breast cancer risk. To identify potential causal variants related to breast cancer risk, we performed a high resolution fine-mapping analysis ...
    • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 

      Dadaev, T; Saunders, EJ; Newcombe, PJ; Anokian, E; Leongamornlert, DA; Brook, MN; Cieza-Borrella, C; Mijuskovic, M; Wakerell, S; Olama, AAA; Schumacher, FR; Berndt, SI; Benlloch, S; Ahmed, M; Goh, C; Sheng, X; Zhang, Z; Muir, K; Govindasami, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, P; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, G; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Hakansson, N; West, C; Dunning, AM; Burnet, N; Mucci, L; Giovannucci, E; Andriole, G; Cussenot, O; Cancel-Tassin, G; Koutros, S; Freeman, LEB; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, B; Kerns, S; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Fachal, L; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weisher, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Slavov, C; Mitev, V; Parliament, M; Singhal, S; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Kierzek, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Kraft, P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Freedman, M; Wiklund, F; Chanock, S; Henderson, BE; Easton, DF; Haiman, CA; Eeles, RA; Conti, DV; Kote-Jarai, Z (2018-06-11)
      Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable ...
    • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. 

      Horne, HN; Chung, CC; Zhang, H; Yu, K; Prokunina-Olsson, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Fletcher, O; Johnson, N; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; González-Neira, A; Anton-Culver, H; Neuhausen, SL; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Nevanlinna, H; Khan, S; Matsuo, K; Iwata, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; Chenevix-Trench, G; kConFab/AOCS Investigators; Wu, AH; Ven den Berg, D; Smeets, A; Zhao, H; Chang-Claude, J; Rudolph, A; Radice, P; Barile, M; Couch, FJ; Vachon, C; Giles, GG; Milne, RL; Haiman, CA; Marchand, LL; Goldberg, MS; Teo, SH; Taib, NAM; Kristensen, V; Borresen-Dale, A-L; Zheng, W; Shrubsole, M; Winqvist, R; Jukkola-Vuorinen, A; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Czene, K; Darabi, H; Hollestelle, A; Martens, JWM; Li, J; Lu, W; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Shah, M; Luccarini, C; Baynes, C; Harrington, P; Kang, D; Choi, J-Y; Hartman, M; Chia, KS; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Sangrajrang, S; Brennan, P; Slager, S; Yannoukakos, D; Shen, C-Y; Hou, M-F; Swerdlow, A; Orr, N; Simard, J; Hall, P; Pharoah, PDP; Easton, DF; Chanock, SJ; Dunning, AM; Figueroa, JD (2016-01)
      The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, ...
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. 

      Vigorito, E; Kuchenbaecker, KB; Beesley, J; Adlard, J; Agnarsson, BA; Andrulis, IL; Arun, BK; Barjhoux, L; Belotti, M; Benitez, J; Berger, A; Bojesen, A; Bonanni, B; Brewer, C; Caldes, T; Caligo, MA; Campbell, I; Chan, SB; Claes, KBM; Cohn, DE; Cook, J; Daly, MB; Damiola, F; Davidson, R; Pauw, AD; Delnatte, C; Diez, O; Domchek, SM; Dumont, M; Durda, K; Dworniczak, B; Easton, DF; Eccles, D; Edwinsdotter Ardnor, C; Eeles, R; Ejlertsen, B; Ellis, S; Evans, DG; Feliubadalo, L; Fostira, F; Foulkes, WD; Friedman, E; Frost, D; Gaddam, P; Ganz, PA; Garber, J; Garcia-Barberan, V; Gauthier-Villars, M; Gehrig, A; Gerdes, A-M; Giraud, S; Godwin, AK; Goldgar, DE; Hake, CR; Hansen, TVO; Healey, S; Hodgson, S; Hogervorst, FBL; Houdayer, C; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jacobs, L; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Vijai, J; Karlan, BY; Kast, K; KConFab Investigators; Khan, S; Kwong, A; Laitman, Y; Lester, J; Lesueur, F; Liljegren, A; Lubinski, J; Mai, PL; Manoukian, S; Mazoyer, S; Meindl, A; Mensenkamp, AR; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Park, SK; Paulsson-Karlsson, Y; Pedersen, IS; Peissel, B; Peterlongo, P; Pfeiler, G; Phelan, CM; Piedmonte, M; Poppe, B; Pujana, MA; Radice, P; Rennert, G; Rodriguez, GC; Rookus, MA; Ross, EA; Schmutzler, RK; Simard, J; Singer, CF; Slavin, TP; Soucy, P; Southey, M; Steinemann, D; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vratimos, A; Weitzel, JN; McGuffog, L; Kirk, J; Toland, AE; Hamann, U; Lindor, N; Ramus, SJ; Greene, MH; Couch, FJ; Offit, K; Pharoah, PDP; Chenevix-Trench, G; Antoniou, AC (2016-01)
      Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale ...
    • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. 

      Shi, J; Zhang, Y; Zheng, W; Michailidou, K; Ghoussaini, M; Bolla, MK; Wang, Q; Dennis, J; Lush, M; Milne, RL; Shu, X-O; Beesley, J; Kar, S; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Zhao, Z; Guo, X; Benitez, J; Beeghly-Fadiel, A; Blot, W; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brinton, L; Broeks, A; Brüning, T; Burwinkel, B; Cai, H; Canisius, S; Chang-Claude, J; Choi, J-Y; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Droit, A; Dork, T; Fasching, PA; Fletcher, O; Flyger, H; Fostira, F; Gaborieau, V; García-Closas, M; Giles, GG; Mervi Grip; Guenel, P; Haiman, CA; Hamann, U; Hartman, M; Miao, H; Hollestelle, A; Hopper, JL; Hsiung, C-N; kConFab Investigators; Ito, H; Jakubowska, A; Johnson, N; Torres, D; Kabisch, M; Kang, D; Khan, S; Knight, JA; Kosma, V-M; Lambrechts, D; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Le Marchand, L; Margolin, S; Marme, F; Matsuo, K; McLean, C; Meindl, A; Muir, K; Neuhausen, SL; Nevanlinna, H; Nord, S; Børresen-Dale, A-L; Olson, JE; Orr, N; van den Ouweland, AMW; Peterlongo, P; Putti, TC; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Shen, C-Y; Hou, M-F; Shrubsole, MJ; Southey, MC; Swerdlow, A; Teo, SH; Thienpont, B; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Truong, T; Tseng, C-C; Wen, W; Winqvist, R; Wu, AH; Yip, CH; Zamora, PM; Zheng, Y; Floris, G; Cheng, C-Y; Hooning, MJ; Martens, JWM; Seynaeve, C; Kristensen, VN; Hall, P; Pharoah, PDP; Simard, J; Chenevix-Trench, G; Dunning, AM; Antoniou, AC; Easton, DF; Cai, Q; Long, J (2016-09)
      Previous genome-wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. ...
    • First evaluation of the feasibility of MLC tracking using ultrasound motion estimation. 

      Fast, MF; O'Shea, TP; Nill, S; Oelfke, U; Harris, EJ (2016-08)
      To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB, Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.The Clarity calibration and quality assurance phantom was ...
    • A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

      Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04)
      The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. ...
    • First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. 

      Dwivedi, RC; St Rose, S; Roe, JWG; Chisholm, E; Elmiyeh, B; Nutting, CM; Clarke, PM; Kerawala, CJ; Rhys-Evans, PH; Harrington, KJ; Kazi, R (2011-03)
      BACKGROUND: Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking ...
    • A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection 

      Salehi-Reyhani, A; Kaplinsky, J; Burgin, E; Novakova, M; deMello, AJ; Templer, RH; Parker, P; Neil, MAA; Ces, O; French, P; Willison, KR; Klug, D (ROYAL SOC CHEMISTRY, 2011)
      We have developed a generic platform to undertake the analysis of protein copy number from single cells. The approach described here is ‘all-optical’ whereby single cells are manipulated into separate analysis chambers ...
    • First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. 

      Sessa, C; Shapiro, GI; Bhalla, KN; Britten, C; Jacks, KS; Mita, M; Papadimitrakopoulou, V; Pluard, T; Samuel, TA; Akimov, M; Quadt, C; Fernandez-Ibarra, C; Lu, H; Bailey, S; Chica, S; Banerji, U (2013-07)
      PURPOSE:A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...
    • First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. 

      Pollack, SM; Lu, H; Gnjatic, S; Somaiah, N; O'Malley, RB; Jones, RL; Hsu, FJ; Ter Meulen, J (2017-10)
      Effective induction of antitumor T cells is a pivotal goal of cancer immunotherapy. To this end, lentiviral vectors (LV) are uniquely poised to directly prime CD8 T-cell responses via transduction of dendritic cells in ...
    • A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

      Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09)
      Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...
    • First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. 

      Tomasello, G; Valeri, N; Ghidini, M; Smyth, EC; Liguigli, W; Toppo, L; Mattioli, R; Curti, A; Hahne, JC; Negri, FM; Panni, S; Ratti, M; Lazzarelli, S; Gerevini, F; Colombi, C; Panni, A; Rovatti, M; Treccani, L; Martinotti, M; Passalacqua, R (2017-12-04)
      Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose ...
    • A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. 

      Mateo, J; Ganji, G; Lemech, C; Burris, HA; Han, S-W; Swales, K; Decordova, S; DeYoung, MP; Smith, DA; Kalyana-Sundaram, S; Wu, J; Motwani, M; Kumar, R; Tolson, JM; Rha, SY; Chung, HC; Eder, JP; Sharma, S; Bang, Y-J; Infante, JR; Yan, L; de Bono, JS; Arkenau, H-T (2017-10)
      Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of ...